Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Sees Steady Switch to Nesp Biosame, but Biosimilars Closing in at Full Steam
September 18, 2020
- Santen Gobbles Up US Ophthalmic Player for US$225 Million
September 18, 2020
- Towa, Nichi-Iko Recalling Some Metformin Products over Carcinogen Risks, Follow 2 Makers
September 17, 2020
- Nichi-Iko to Resume Normal Shipments of Cefazolin Starting October 1
September 17, 2020
- Takeda Opens New Manufacturing Site for Cell Therapy Products in Boston
September 17, 2020
- Takeda to Offload TachoSil to Corza Health
September 17, 2020
- Amgen Files Erenumab for Migraine Prevention in Japan
September 17, 2020
- SanBio to Start Talks with PMDA over Late-Stage Study of SB623 in Ischemic, Hemorrhagic Strokes: COO
September 17, 2020
- Prescriptions for Respiratory Meds, Antibiotics Down Over 30% in August: Survey
September 16, 2020
- Daiichi Sankyo Begins PII Study of ADC Patritumab for HER3-Positive Colorectal Cancer
September 16, 2020
- Novartis’ Mayzent now Available in Japan for Secondary Progressive MS
September 15, 2020
- J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
September 15, 2020
- Incyte Files Japan NDA for Pemigatinib for Cholangiocarcinoma
September 15, 2020
- Lilly Japan to Run Its First Voluntary Redundancy Program, 10% of Sales Force Targeted?
September 15, 2020
- AstraZeneca, PMDA Discussing Restart of COVID-19 Vaccine Trial in Japan
September 14, 2020
- Additional Dosage of Edoxaban Filed in Japan for Elderly with High Bleeding Risk
September 14, 2020
- Nihon Chouzai’s Standard Formulary Service Expands to 17 Therapeutic Classes, Monitor Hospitals Moving to Craft Own Lists
September 11, 2020
- 1st Japanese COVID-19 Patient Enrolled in Global PIII of Ultomiris: Alexion
September 11, 2020
- Enspryng Reduces Risk and Severity of Relapse by 79% in NMOSD Patients: Chugai
September 11, 2020
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…